NVAX's Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial
Published
Today's Daily Dose brings you news about encouraging results of Novavax' Covid-19 vaccine candidate; FDA lifting the clinical hold on Bellicum's BPX-601 study; and near-term catalysts of Ayala Pharma and AzurRx.
Full Article